Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01805037|
Recruitment Status : Unknown
Verified April 2015 by Adam Petrich, Northwestern University.
Recruitment status was: Recruiting
First Posted : March 5, 2013
Last Update Posted : April 30, 2015
Seattle Genetics, Inc.
Information provided by (Responsible Party):
Adam Petrich, Northwestern University
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||January 2016|
|Study Completion Date :||No date given|